Wells Fargo & Company Lowers uniQure (NASDAQ:QURE) Price Target to $30.00

uniQure (NASDAQ:QURE) had its price objective dropped by analysts at Wells Fargo & Company from $35.00 to $30.00 in a report released on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 128.22% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. The Goldman Sachs Group increased their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Cantor Fitzgerald increased their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Stifel Nicolaus increased their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. Mizuho increased their target price on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Stock Up 8.9 %

uniQure stock opened at $13.15 on Friday. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a 50 day moving average of $15.05 and a 200-day moving average of $9.81. The stock has a market capitalization of $640.73 million, a PE ratio of -2.65 and a beta of 0.38. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Activity

In other news, CFO Christian Klemt sold 2,916 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the transaction, the chief executive officer now directly owns 571,188 shares in the company, valued at $6,111,711.60. The trade was a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 55,915 shares of company stock valued at $588,112 over the last ninety days. 4.74% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

A number of hedge funds have recently bought and sold shares of the business. Voloridge Investment Management LLC bought a new position in uniQure during the fourth quarter worth about $3,129,000. Woodline Partners LP bought a new position in uniQure during the fourth quarter worth about $2,484,000. Two Sigma Advisers LP increased its position in uniQure by 1.4% during the fourth quarter. Two Sigma Advisers LP now owns 756,900 shares of the biotechnology company’s stock worth $13,367,000 after acquiring an additional 10,400 shares during the period. Two Sigma Investments LP increased its position in uniQure by 9.2% during the fourth quarter. Two Sigma Investments LP now owns 878,884 shares of the biotechnology company’s stock worth $15,521,000 after acquiring an additional 73,988 shares during the period. Finally, Stempoint Capital LP bought a new position in uniQure during the fourth quarter worth about $1,589,000. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.